Neurogene Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Neurogene Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-86.2×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 80% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-20.8×Operating cash was negative last year, while some debt falls due within a year.
Lower than 55% of Healthcare companies in United States.
Cash Cushion Ratio
+53%Cash, after subtracting all debt, equals 53% of its market value (net cash).
Higher than 77% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Neurogene Inc. made a loss over the last year. Neurogene Inc. owes $0.11 for every $1 it owns. Neurogene Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossNeurogene Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.24The share price is 2.24 times Neurogene Inc.'s book value per share, lower than 54% of Healthcare companies in United States.
Market cap
$486 MThe total market value of all of Neurogene Inc.'s shares at today's price (share price × number of shares), larger than 54% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$217 MWhat Neurogene Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$10.85Net worth divided by the number of shares. The share price of $24.28 is 2.2 times this, which is the P/B above.
Return on equity (ROE)
-45.3%Neurogene Inc. lost 45.3% of its shareholders' money over the last year, higher than 52% of Healthcare companies in United States.
Owes vs Owns
0.11×Neurogene Inc. owes $0.11 for every $1 it owns (low), lower than 85% of Healthcare companies in United States.
Dividend yield
NoneNeurogene Inc. does not currently pay a dividend.
Profit growth
LossNeurogene Inc. made a loss in each of the last two years.
Interest cover
Not coveredNeurogene Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashNeurogene Inc. held $258 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Neurogene Inc.: $486 M ÷ $217 M (30 Jun 2026) = 2.2.
What is Neurogene Inc.'s return on equity?
Neurogene Inc. lost 45.3% of its shareholders' money over the last year, higher than 52% of Healthcare companies in United States.
How much does Neurogene Inc. owe compared with what it owns?
Neurogene Inc. owes $0.11 for every $1 it owns (low), lower than 85% of Healthcare companies in United States.
Does Neurogene Inc. pay a dividend?
No. Neurogene Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.